Skip to content

Value of electroacupuncture combined with non-steroidal drugs in adjuvant treatment of breast cancer

Value of electroacupuncture combined with non-steroidal drugs in adjuvant treatment of breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020541
Enrollment
Unknown
Registered
2019-01-07
Start date
2018-04-13
Completion date
Unknown
Last updated
2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Group 1:electroacupuncture combined with non-steroidal drug
Group 2:simple non-steroidal drugs

Sponsors

Guangdong Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing breast cancer surgery; 2. Aged 18-75 years old; 3. BMI index 18-30kg/m2; 4. ASA grade I to III; 5. Voluntary signing of informed consent.

Exclusion criteria

Exclusion criteria: 1) Electroacupuncture stimulates contraindications, including partial skin damage, infection, or implantation of electrophysiological devices in the body; 2) communication barriers, unable to cooperate with researchers, such as language understanding disorders, mental illness, etc.; 3) Patients with unstable angina pectoris and myocardial infarction within 3 months; those with cardiac function NYHA classification =3; 4) preoperative visit blood pressure = 180/110 mm Hg (WHO-ISH hypertension guide level 3 hypertension); 5) Patients with a history of peptic ulcer/bleeding/perforation; 6) severe liver and kidney function abnormalities (severe liver function abnormalities: any of ALT, AST, ALP or TBIL > 2 times the upper limit of normal value; severe renal dysfunction: Cr clearance rate 177umol/L); 7) Patients known to be allergic to non-steroidal drugs; 8) Participated in other clinical trials within 3 months prior to enrollment in the study.

Design outcomes

Primary

MeasureTime frame
Basic life activity ability (BADL) score 24 hours after surgery;

Countries

China

Contacts

Public ContactBimei He

Guangdong Provincial Hospital of Traditional Chinese Medicine

hebimei02@163.com+86 13719190492

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026